ABBVIE INC. (ABBV)
AbbVie Inc. (ABBV) is a global biopharmaceutical company founded in 2013 as a spin-off from Abbott Laboratories. It specializes in the research, development, and marketing of innovative medicines across a range of therapeutic areas, including immunology, oncology, virology, and neuroscience. AbbVie is known for its flagship product, Humira, a leading treatment for autoimmune diseases. The company focuses on advancing scientific discoveries to deliver novel therapies and improve patient outcomes worldwide.
Dividend History
Investors can expect a dividend payout of $1.64 per share, scheduled to be distributed in 55 days on November 14, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| November 14, 2025 | $1.64 | 2025-10-15 | 2025-10-15 |
| August 15, 2025 | $1.64 | 2025-07-15 | 2025-07-15 |
| May 15, 2025 | $1.64 | 2025-04-15 | 2025-04-15 |
| February 14, 2025 | $1.64 | 2025-01-15 | 2025-01-15 |
| November 15, 2024 | $1.55 | 2024-10-15 | 2024-10-15 |
Dividends Summary
- ABBVIE INC. has issued 52 dividend payments over the past 12 years
- The most recent dividend was paid 36 days ago, on August 15, 2025
- The highest dividend payed out to investors during this period was $1.64 per share
- The average dividend paid during this period was $1.00 per share.
Company News
The global topical drugs Contract Development and Manufacturing Organization (CDMO) market is projected to grow from $46.32 billion in 2024 to $136.71 billion by 2034, with a CAGR of 11.43%. Key growth drivers include increasing demand for non-invasive therapies, advancements in drug delivery technologies, and expanding pharmaceutical outsourcing.
AbbVie is a pharmaceutical company with a strong dividend track record, growing payouts, and a robust drug development pipeline. While its stock isn't currently cheap, it offers promising long-term investment potential.
AbbVie announced a quarterly cash dividend of $1.64 per share, payable on November 14, 2025, to stockholders of record as of October 15, 2025. The company has increased its dividend by 310% since its inception in 2013 and is a member of the S&P Dividend Aristocrats Index.
The healthcare sector is experiencing low valuations and potential for a quiet rebound, with improving technical indicators and significant institutional investment despite ongoing political and economic challenges.
The article discusses the Invesco Large Cap Value ETF (PWV), which provides broad exposure to the large-cap value segment of the market. It highlights the fund's investment strategy, performance, and risk profile, as well as compares it to similar ETFs like Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Value ETF (VTV).
